An osteoclast-targeting agent for imaging and therapy of bone metastasis

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 17, 2008, Pages 4789-4793

  Liu, Wei ^a   Hajibeigi, Asghar ^a   Lin, Mai ^a   Rostollan, Cynthia L ^a   Kovacs, Zoltan ^b   Öz, Orhan K ^a   Sun, Xiankai ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bifunctional chelator; Bisphosphonate; Bone metastasis; Imaging agent; Indium 111; Osteoclast

Indexed keywords

1,4,7,10 TETRAAZACYCLOTETRADECANE N,N',N'',N''' TETRAACETIC ACID BIPHOSPHONATE CONJUGATE; INDIUM 111; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; BONE METASTASIS; COMPARATIVE STUDY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG UPTAKE; IMAGING; MOUSE; NONHUMAN; OSTEOCLAST; TISSUE DISTRIBUTION;

ANIMALS; BONE NEOPLASMS; CELLS, CULTURED; DIAGNOSTIC IMAGING; DIPHOSPHONATES; HETEROCYCLIC COMPOUNDS, 1-RING; INDIUM RADIOISOTOPES; MALE; MICE; MICE, INBRED BALB C; OSTEOCLASTS;

MUS;

EID: 49949087770     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.07.092     Document Type: Article

References (36)

1. Hobolth L., Nemery M., Albrectsen J., and Hasbak P. Clin. Nucl. Med. 33 (2008) 61
2. Moore A.E., Blake G.M., and Fogelman I. J. Nucl. Med. 49 (2008) 375
3. Peterson J.J., Kransdorf M.J., and O'Connor M.I. Clin. Orthop. Relat. Res. (2003) S120
4. Saeed S., Haq S., Sohaib M., and Khan A.N. Clin. Nucl. Med. 26 (2001) 930
5. Silverman S.L., and Maricic M. Semin. Arthritis Rheum. 37 (2007) 1
6. Berenson J.R., Rosen L.S., Howell A., Porter L., Coleman R.E., Morley W., Dreicer R., Kuross S.A., Lipton A., and Seaman J.J. Cancer 91 (2001) 1191
7. Yeh H.S., and Berenson J.R. Eur. J. Cancer 42 (2006) 1554
8. Body J.J. Cancer 88 (2000) 3054
9. Kohno N. Int. J. Clin. Oncol. 13 (2008) 18
10. Penel N., Dewas S., Doutrelant P., Clisant S., Yazdanpanah Y., and Adenis A. Support Care Cancer 16 (2008) 387
11. Pinkerton J.V., and Dalkin A.C. Am. J. Obstet. Gynecol. 197 (2007) 559
12. Hosain F., Spencer R.P., Couthon H.M., and Sturtz G.L. J. Nucl. Med. 37 (1996) 105
13. Clezardin P., Fournier P., Boissier S., and Peyruchaud O. Curr. Med. Chem. 10 (2003) 173
14. Stresing V., Daubine F., Benzaid I., Monkkonen H., and Clezardin P. Cancer Lett. 257 (2007) 16
15. Schwartz Z., Shani J., Soskolne W.A., Touma H., Amir D., and Sela J. J. Nucl. Med. 34 (1993) 104
16. De Leon-Rodriguez L.M., and Kovacs Z. Bioconjug. Chem. 19 (2008) 391
17. Forster G.J., Santos E.B., Smith-Jones P.M., Zanzonico P., and Larson S.M. J. Nucl. Med. 47 (2006) 140
18. Li M., Meares C.F., Salako Q., Kukis D.L., Zhong G.R., Miers L., and DeNardo S.J. Cancer Res. 55 (1995) 5726s
19. Kubicek V., Rudovsky J., Kotek J., Hermann P., Vander Elst L., Muller R.N., Kolar Z.I., Wolterbeek H.T., Peters J.A., and Lukes I. J. Am. Chem. Soc. 127 (2005) 16477
20. Vitha T., Kubicek V., Hermann P., Elst L.V., Muller R.N., Kolar Z.I., Wolterbeek H.T., Breeman W.A., Lukes I., and Peters J.A. J. Med. Chem. 51 (2008) 677
21. Page P.C., McKenzie M.J., and Gallagher J.A. J. Org. Chem. 66 (2001) 3704
22. Andre J.P., Geraldes C.F., Martins J.A., Merbach A.E., Prata M.I., Santos A.C., de Lima J.J., and Toth E. Chemistry 10 (2004) 5804
23. Vitha T., Kubicek V., Hermann P., Kolar Z.I., Wolterbeek H.T., Peters J.A., and Lukes I. Langmuir 24 (2008) 1952
24. Chemical synthesis and characterization data.(a) General methods.All chemicals, solvents, and reagents were purchased from Sigma-Aldrich (St. Louis, MO) and used directly without further purification unless otherwise noted. 1,4,7,10-Tetraazacyclododecane-1,4,7-tris-(t-butyl acetate) (DO3A-t-Bu-ester) was obtained from Macrocylic Inc. (Dallas, TX). Silica gel 60 (70-230 mesh) used for column chromatography was obtained from Sigma-Aldrich. Analytical thin-layer chromatography (TLC) was performed using Merck 60 F254 silica gel (precoated sheets, 0.2 mm thick) (Lawrence, KS) and Whatman MCK 18F reversed-phase plates (Maidstone, Kent, UK).
25. Liu S., Pietryka J., Ellars C.E., and Edwards D.S. Bioconjug. Chem. 13 (2002) 902
26. Sun X., Fang H., Li X., Rossin R., Welch M.J., and Taylor J.S. Bioconjug. Chem. 16 (2005) 294
27. 111In-DO3A-BP was determined by adding 5 μL of the complex to a solution containing 500 μL of Milli-Q water and 500 μL of octanol (obtained from a saturated octanol/water solution) (n = 10). The sample vials were shaken for 1 h at room temperature. From each vial, aliquots of 100 μL each were removed from the octanol phase and the water phase, respectively, and counted separately. The partition coefficient was calculated as the ratio of counts in the octanol fraction to the counts in the water fraction. An average of log P value was obtained from the 10 samples.
28. Rogers M.J., Gordon S., Benford H.L., Coxon F.P., Luckman S.P., Monkkonen J., and Frith J.C. Cancer 88 (2000) 2961
29. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., Golub E., and Rodan G.A. J. Clin. Invest. 88 (1991) 2095
30. Holtrop M.E., and King G.J. Clin. Orthop. Relat. Res. 123 (1977)
31. Takeshita S., Kaji K., and Kudo A. J. Bone Miner. Res. 15 (2000) 1477
32. 111In-DO3A-BP was measured by counting the cell lysates in a γ-counter. The protein concentration in each lysate was determined using the Bio-Rad Protein Assay. The assay was repeated 5 times, and all data were pooled for analysis.
33. 111In-DO3A-BP was diluted with PBS (10 mM) to prepare the injection doses. Each mouse was injected with ca. 5 μCi of radioactivity in 100 μL via the tail vein. The mice were anesthetized prior to sacrifice at each time point (1, 4, 24, and 48 h; n = 4 per time point). Organs of interest were removed, weighed, and counted by a γ-counter. Standards were prepared and counted along with the samples to calculate the percent injected dose per gram (%ID/g) and percent injected dose per organ (%ID/organ). The animals of the last time point groups were housed in metabolic cages (4 mice per cage) to collect urine and feces at 1, 4, 24, and 48 h pi to evaluate the excretion route and stability of the compound.
34. Ogawa K., Mukai T., Inoue Y., Ono M., and Saji H. J. Nucl. Med. 47 (2006) 2042
35. Santini D., Galluzzo S., Vincenzi B., Schiavon G., Fratto E., Pantano F., and Tonini G. Ann. Oncol. 18 (2007) vi164
36. Whyte M.P., McAlister W.H., Novack D.V., Clements K.L., Schoenecker P.L., and Wenkert D. J. Bone Miner. Res. (2008)